# MOMA Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/moma-therapeutics

- Industry: Biopolymers
- Headquarters: Brighton, US
- Website: www.momatx.com
- Total disclosed funding: $236M
- Latest round: Series B (May 10, 2022)
- Investors on record: 12

## About

MOMA Therapeutics, Inc. is a biotechnology company focused on discovering and developing precision medicines that target molecular machines involved in various human diseases, aiming to create innovative therapies for unmet medical needs.MOMA Therapeutics, Inc. specializes in precision medicine, established in 2020 and headquartered in Brighton, US. The company has completed 2 deals, with its most recent funding round being a Series B of USD 150.00 mn on May 10, 2022, led by Goldman Sachs Merchant Banking Division. The founder, Timur Yusufzai, has a background that includes other entrepreneurial ventures. Asit Parikh serves as the CEO.MOMA Therapeutics focuses on the discovery and development of precision medicines targeting molecular machines involved in human disease, offering innovative therapies aimed at unlocking the potential of these machines. Their products serve healthcare providers and pharmaceutical partners globally, addressing areas with critical unmet medical needs across North America, Europe, and Asia.MOMA Therapeutics generates revenue through strategic partnerships and collaborations within the biopharmaceutical sector, primarily working with pharmaceutical companies and research institutions. Their revenue model includes milestone payments, licensing agreements, and potential royalties on successful therapeutic products, structured to support the advancement of their innovative pipeline through clinical trials.The latest funding of USD 150.00 mn raised in May 2022 will facilitate the advancement of multiple precision oncology programs in the clinic. MOMA Therapeutics is also looking to expand its reach further into global markets, specifically targeting regions in Europe and Asia by 2024, with an emphasis on launching new products in the oncology space.

## Funding rounds

- Series B, May 10, 2022, $150M — Alexandria Venture Investments, Invus [DUP], Third Rock Ventures, Nextech, Goldman Sachs Asset Management, Casdin Capital, Pavilion Capital, Rock Springs Capital, Cormorant Asset Management, Section 32, LifeSci Partners, Creacion Ventures
- Series A, Apr 16, 2020, $86M — Third Rock Ventures, Nextech, Casdin Capital, Rock Springs Capital, Cormorant Asset Management, Creacion Ventures

## Investors

- Third Rock Ventures (https://capitalatlas.ai/funds/third-rock-ventures) — Series A, Series B
- Nextech (https://capitalatlas.ai/funds/nextech) — Series A, Series B
- Casdin Capital (https://capitalatlas.ai/funds/casdin-capital) — Series A, Series B
- Rock Springs Capital — Series A, Series B
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series A, Series B
- Creacion Ventures (https://capitalatlas.ai/funds/creacion-ventures) — Series A, Series B
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series B
- Invus [DUP] — Series B
- Goldman Sachs Asset Management (https://capitalatlas.ai/funds/goldman-sachs-asset-management) — Series B
- Pavilion Capital — Series B
- Section 32 (https://capitalatlas.ai/funds/section-32) — Series B
- LifeSci Partners (https://capitalatlas.ai/funds/lifesci-partners) — Series B